VivoSim Labs, Inc. (NASDAQ: VIVS) announced it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to raise approximately $4 million in gross proceeds through a private placement. The transaction involves the issuance of 4,705,883 shares of common stock, or common stock equivalents, and accompanying warrants, priced at a combined $0.85 per share. The warrants are exercisable following shareholder approval and expire five years after their initial exercise date, with an exercise price of $0.85 per share. Additionally, subject to shareholder approval, the company agreed to amend certain existing May 2024 warrants by reducing their exercise price from $9.60 to $0.85 per share.
The offering is expected to close on or about July 17, 2026, subject to customary closing conditions. VivoSim intends to use the net proceeds for working capital and general corporate purposes. The securities were offered in a private placement exempt from Securities Act registration requirements, and the company has agreed to file a resale registration statement with the U.S. Securities and Exchange Commission covering the shares and warrant shares issued in the transaction. According to the press release, the full details are available at https://ibn.fm/7Ov0B.
VivoSim Labs is a pharmaceutical and biotechnology services company focused on providing testing of drugs and drug candidates in three-dimensional human tissue models of liver and intestine. The company offers partners liver and intestinal toxicology insights using its new approach methodologies models. VivoSim anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration's roadmap to refine animal testing requirements in favor of these non-animal methods. The company operates from San Diego, CA, and more information can be found at https://vivosim.ai/.
This private placement arrives at a critical juncture for VivoSim as it seeks to capitalize on regulatory shifts away from animal testing. The FDA's modernization efforts, including the FDA Modernization Act 2.0, have opened pathways for alternative testing methods, and VivoSim's 3D tissue models position the company to benefit from this trend. The involvement of a healthcare-focused institutional investor signals confidence in VivoSim's technology and market potential. The proceeds will likely support research and development, as well as commercial scaling of its testing services.
The amendment of existing warrants at a lower exercise price aligns incentives for early investors and may facilitate future capital raising. However, the transaction requires shareholder approval, adding a layer of uncertainty. If approved, the dilution from the new shares and warrants could affect existing shareholders, but the capital infusion provides runway for VivoSim to execute its strategy. The company's focus on non-animal testing methods addresses growing ethical and regulatory pressures, making it a compelling player in the evolving drug development landscape.
